<?xml version="1.0" encoding="UTF-8" ?><dbgapss xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbgapssws.1.0.xsd"><Study uid="39186" whole_study_id="39186" phs="002469" v="1" p="1" createDate="2020-08-21T09:18:15-05:00" completedByGPADate="2021-06-14T15:43:40-05:00" modDate="2022-01-25T16:16:23-05:00" maxParentChildStudyModDate="2022-01-25T16:16:23-05:00" num_participants=""><StudyInfo accession="phs002469.v1.p1" parentAccession="phs002469.v1.p1"><BioProject id="PRJNA739766" entrez_id="739766" type="bp_admin_access"/><BioProject id="PRJNA739767" entrez_id="739767" type="bp_data_submission"/><StudyNameEntrez>Clonal hematopoiesis of indeterminate potential, incident cardiovascular outcomes, and statin therapy among people living with HIV in REPRIEVE</StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="Yes"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="Yes"><StudyType22 name="ncbi_for_sequence"/><StudyType22 name="whole_targ_exome"/></StudyType21><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="Yes"><StudyType22 name="genotype_calls_from_sequence"/><StudyType22 name="somatic_snv"/></StudyType21><StudyType21 name="subject_samples" chosen="Yes"><StudyType22 name="germline"/><StudyType22 name="tumor_normal"/><StudyType22 name="dna"/></StudyType21><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><StudyTypes><StudyType>phenotype_data</StudyType><StudyType>genotype_data</StudyType><StudyType>germline</StudyType><StudyType>tumor_normal</StudyType><StudyType>dna</StudyType><StudyType>genotype_calls_from_sequence</StudyType><StudyType>somatic_snv</StudyType><StudyType>whole_exome</StudyType><StudyType>array_derived_expression</StudyType><StudyType>sra</StudyType></StudyTypes><SraStorages><SraStorage location="NCBI"/></SraStorages><Funding>HL151283</Funding></StudyInfo><Authority><ICs><IC id="12" name="NHLBI" is_funding_ic="true" is_admin_ic="true" primary="true"/></ICs><Persons><Person nedid="PNATARAJAN" aid="2" auth="eRA" login="PNATARAJAN" fname="Pradeep" mname="" lname="Natarajan" email="PNATARAJAN@PARTNERS.ORG"><Role allow_direct_access="true">PI</Role><Organization>MASSACHUSETTS GENERAL HOSPITALBROAD INSTITUTE, INC.</Organization></Person><Person nedid="2002149404" aid="1" auth="cit" login="ketemaf2" fname="Fassil" mname="" lname="Ketema" email="fassil.ketema@nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person aid="8" auth="virtual" fname="Lan" lname="Nguyen" email="ltn@broadinstitute.org"><Role>PI_ASSIST</Role><Organization/></Person><Person nedid="2001545300" aid="1" auth="cit" login="lic17" fname="Chengyuan" mname="" lname="Press" email="chanel.press@nih.gov"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="true" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="none"><acknowledgement_statement>The REPRIEVE Study is supported by NIH/NHLBI (U01HL123336; U01HL123339), the Office of Aids Research, Kowa Pharmaceuticals America, Inc. (119127), Gilead Sciences, Inc. (CO-US-311-1787), and ViiV Healthcare. Funding for whole exome sequencing was provided by R01HL151283. The study investigators thank the study participants, site investigators and staff, and study-associated personnel for their ongoing participation in the trial. Publications resulting from this data should cite: 
&#8220;Steven K. Grinspoon, MD, a Kathleen V. Fitch, MSN, Edgar Turner Overton, MD, et al. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). American Heart Journal 212: 23-35, 2019. The original data can be found in the NIH database of Genotypes and Phenotypes (dbGaP) under the accession number phs______.&#8221; 

</acknowledgement_statement><ic_specific_access_term>Use of the data must be related to Cardiovascular Disease and/or HIV.
Requestor must provide documentation of local IRB approval.
Only full or expedited approvals are acceptable, and an ANNUAL IRB review is required base on the informed consents from the submitting institution.</ic_specific_access_term><DUC universal_duc="Yes"><File full_url="https://dbgap.ncbi.nlm.nih.gov/aa/docs/Static_DUC_20190419.pdf" filename="Static_DUC_20190419.pdf" content-type="application/pdf"/></DUC><DUC_PDF universal_duc="Yes"><File full_url="https://dbgap.ncbi.nlm.nih.gov/aa/docs/Static_DUC_20190419.pdf" filename="Static_DUC_20190419.pdf" content-type="application/pdf"/></DUC_PDF><GSR_Access gsr_mode="contr_access" gsr_mode_label="Controlled-access (GSR are sensitive according to the Institutional Certification)"/><ConsentGroup uid="4589" CGType="cg_class_DS" title="Disease-Specific (Cardiovascular Disease and/or Human Immunodeficiency Virus, IRB)" name="DS-CVD-HIV-IRB" dac_uid="56" dac_name="NHLBI" irb-approval-required="Yes"><Use-Restriction>Use of the data must be related to Cardiovascular Disease and/or Human Immunodeficiency Virus.
Requestor must provide documentation of local IRB approval.

Use of the data must be related to Cardiovascular Disease and/or HIV.
Requestor must provide documentation of local IRB approval.
Only full or expedited approvals are acceptable, and an ANNUAL IRB review is required base on the informed consents from the submitting institution.</Use-Restriction></ConsentGroup></Policy><SRA/><Documents/><Status uid="14" name="completed_by_gpa" title="Completed by GPA"/></Study></dbgapss>